- 询价
- 辰辉创聚生物®️
- 中国
- NBAB-012351
- 2026年07月10日
- IHC, IP, WB
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Recombinant Human Phospho-Vimentin(pS34) protein
- 形态：
liquid
- 保存条件：
见COA
- 克隆性：
单克隆
- 保质期：
见COA
- 库存：
大量
- 供应商：
北京辰辉创聚生物技术有限公司
- 应用范围：
IHC, IP, WB
- 抗体英文名：
Anti-Phospho-Vimentin(pS34) Monoclonal Antibody
- 抗体名：
抗Phospho-Vimentin(pS34)单克隆抗体
- 规格：
100ul; 500ul; 1ml
| 产品信息
品名：NebuSelect™ Anti-Phospho-Vimentin(pS34) Monoclonal Antibody
别名：Vimentin, VIM
货号：NBAB-012351
品牌：辰辉创聚生物®️
规格：100ul; 500ul; 1ml
| 产品描述
NebuSelect™ Anti-Phospho-Vimentin(pS34) Monoclonal Antibody (Cat# NBAB-012351) was produced in mice immunized with recombinant Human Phospho-Vimentin(pS34) protein, and it reacts with Human. This antibody is validated for IHC, IP, WB.
| 产品属性
Product Category：Mouse MAb
Reactivity：Human
Specificity：Human Phospho-Vimentin(pS34)
Immunogen：Recombinant Human Phospho-Vimentin(pS34) protein
Isotype：Monoclonal Mouse IgG
Purification：Protein A & Protein G Affinity Purification
Buffer：0.2 μm filtered solution in PBS, pH7.4, containing 0.09% Sodium azide, 50% glycerol.
Conjugate：Unconjugated
Applications：IHC, IP, WB
Dilution：IHC-P 1:50～1:500; IP:1:50～1:500; WB: 1:1000～1:5000
Storage：This liquid antibody can be stored at 2℃-8℃ for at least two weeks. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20℃. When reconstituted in sterile pH 7.4 0.01M PBS or antibody diluent, the antibody is stable for at least two weeks at 2-4℃.
For Research Use Only!
To get more information, please contact us freely.
郑重声明：仅用于科学研究，不可用于诊断或治疗。
更多产品细节，请联系我司相关客服人员。
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验largely independent of the surrounding amino-acid sequence. The antibody is phospho-specific but does not cross-react with phospho-serine-containing sequences. The anti-phosphothreonine monoclonal antibody is labeled with Eu3+ Cryptate by Cisbio
【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
IgG单克隆抗体 Phospho-Tau抗体(YA3436)(HY-P83700) www.medchemexpress.cn/antibody/phospho-tau-ser202-thr205-antibody.html 抗磷酸化Tau(Ser202/Thr205) 的IgG单克隆抗体 GFAP抗体(YA755)(HY-P80139) www.medchemexpress.cn/antibody/gfap-mouse-mab.html 抗 GFAP的IgG1单克隆抗体 参考
技术资料暂无技术资料 索取技术资料
